Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1/2, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Efficacy of DZD8586 in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (B-NHL)

Trial Profile

A Phase 1/2, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Efficacy of DZD8586 in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (B-NHL)

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 22 May 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Birelentinib (Primary)
  • Indications B-cell lymphoma; Non-Hodgkin's lymphoma
  • Focus Adverse reactions
  • Acronyms TAI-SHAN1
  • Sponsors Dizal Pharmaceutical

Most Recent Events

  • 15 May 2025 According to a Dizal Pharmaceutical media release, data from this trial will be presented at the 2025 European Hematology Association (EHA) Congress and the 18th International Conference on Malignant Lymphoma (ICML),
  • 01 Apr 2025 According to Dizal biopharma media release, results of its investigational drug candidates DZD8586 have been selected for presentation at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 30-June 3, 2025, in Chicago.
  • 21 Feb 2025 Status changed from recruiting to completed.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top